Dear Editor: I am writing to express my concerns and disappointment about Dr. Norman Levine's editorial comments published in the March issue of Dermatology Times ("The elephant in our living room: What is happening to dermatology?"). As co-chairman of the section on communications for the American Academy of Dermatology, no one is more acutely aware of the changing trends in dermatology than I am. Each time we consider implementing a new communications program for the academy, we must consider the interest of the entire membership. This, of course, has become increasingly difficult over the years due to the fact that our specialty now encompasses medically, surgically, and cosmetically oriented dermatologists.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.